Eli Lilly shares continue to soar thanks to its new weight loss drugs. With sales of Mounjaro and ZepBound continuing to ...
Learn about GLP-1 medications, their benefits, risks, and who should (or shouldn’t) consider using them. Due to its rise in ...
The FDA said it does not plan to take action against GLP-1 compounders for certain violations while it re-evaluates Eli Lilly ...
SINGAPORE – Newer drugs within a class originally developed to treat diabetes are now gaining attention as potential ...
Ozempic, a diabetes medication by Novo Nordisk, has gained popularity for its weight loss effects, sparking debate.
Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...